Celebrex/Bextra Fraud

DEFENDANT NAME: Pfizer Inc., Merck
STOCK SYMBOL: NYSE: PFE
CASE NUMBER: 05-CV-01699-CRB
CASE NAME:
COURT: U.S. District Court of California, U.S. District Court of Massachusetts
PRACTICE AREA: Pharmaceutical Fraud
STATUS: Settled
CLASS PERIOD:
LEAD PLAINTIFF DEADLINE:
DATE FILED: 04/07/05
COURT LOCATION:

Case Settled

On Sept. 25, 2009 the court issued a final ruling in the Bextra litigation, approving an $89 million settlement with Pfizer settling claims the company launched a misleading marketing campaign for its drugs Bextra and Celebrex. The firm was praised for its efforts on behalf of the consumer class.

Hagens Berman filed a class-action lawsuit against Pfizer on behalf of individual consumers and third-party payors who paid for the drug Bextra. The firm was praised by Judge Breyer for its "unstinting" efforts on behalf of the class, adding, "The attorneys on both sides were sophisticated, skilled, professional counsel whose object was to zealously pursue their clients’ interest, but not at the cost of abandoning the appropriate litigation goals, which were to see, whether or not, based upon the merits of the cases, a settlement could be achieved."

Bextra, which has been taken off the market due to side-effect concerns, was used to reduce pain, inflammation and stiffness caused by osteoarthritis and adult rheumatoid arthritis. 

The suit claims that through deceitful marketing, advertising and promotion of Bextra as a superior product to other non-steroidal anti-inflammatory drugs (NSAIDs) - which are much less expensive - Pfizer mislead consumers and physicians into using and prescribing it over the competition. 

The complaint also states that the goal of Pfizer's marketing efforts was to convince medical professionals of Bextra's superiority in order to pressure insurance companies and hospitals to include Bextra on their formulary lists, thus ensuring the drug's success. 

If you paid for or paid a co-pay for Bextra you may be eligible to be part of this suit.

---

The Celebrex/Bextra Fraud Case is In Re: Bextra and Celebrex Marketing Sales Practices and Product Liability Litigation, Case No. 1699, N.D.Ca., MDL


Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.

Back to all cases

Case videos

Case Gallery

Case Timeline

09/25/09: Case Settled

On Sept. 25, 2009 the court issued a final ruling in the Bextra litigation, approving an $89 million settlement with Pfizer settling claims the company launched a misleading marketing campaign for its drugs Bextra and Celebrex. The firm was praised for its efforts on behalf of the consumer class.